Drug Profile
FB 301
Alternative Names: FB-301Latest Information Update: 21 Apr 2020
Price :
$50
*
At a glance
- Originator Academia Sinica
- Developer Cytovance Biologics; Oneness Biotech
- Class Antiallergics; Monoclonal antibodies
- Mechanism of Action IgE receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Allergy in USA (Parenteral)
- 31 Oct 2012 Clinical trials in Hypersensitivity in USA (Parenteral)
- 06 Apr 2011 Investigation in Hypersensitivity in Taiwan (Parenteral)